Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study

• DOI: 10.1080/0284186x.2021.2022201
• Publication Date: 2022-01-04T07:54:51Z
• Authors: A. Abravan; A. Salem; G. Price; C. Faivre-Finn; M. van Herk
• Keywords: Single Center

Introduction Recent studies suggest that immune-related cells can be recruited for anti-tumor functions as well tumor progression and the interplay between systemic inflammation local immune response may play a major role in development of various cancers including lung cancer. Inflammatory markers, such neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), immune-inflammation index (SII) used surrogate biomarkers host status. In this work, associations neutrophils, lymphocytes, platelets, NLR, PLR, SII overall survival (OS) are investigated two cohorts non-small cell cancer (NSCLC) patients treated with fractionated radiotherapy (RT) stereotactic body radiation therapy (SBRT) cohort small (SCLC) RT.Material Methods Data from 2513 were retrospectively analyzed. Baseline (NLR × platelet count) calculated full blood test prior to RT initiation. Cox proportional hazards regression analyses evaluate association markers known clinical factors OS.Results The two-year OS was 42%, 63%, 62% NSCLC RT, SBRT, SCLC cohort. NLR (per 1 unit: hazard [HR]: 1.04, p < 0.05) 100 109/L: HR: 1.01, remained strongest independent multivariable analyses, correcting early-stage locally advanced RT.Discussion This single-center large-cohort study suggests baseline prognostic associated either curative-intent or SBRT RT. External validation is warranted utility these patients' stratification adapting new treatment approaches.